Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1982 1
1983 2
1984 2
1985 2
1986 1
1988 2
1990 3
1991 2
1992 4
1994 3
1996 7
1997 3
1998 1
1999 3
2000 4
2001 11
2002 42
2003 33
2004 42
2005 35
2006 38
2007 41
2008 39
2009 50
2010 44
2011 31
2012 19
2013 26
2014 27
2015 28
2016 35
2017 32
2018 14
2019 11
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

593 results
Results by year
Filters applied: . Clear all
Page 1
Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs
Löscher W. Neurochem Res 2017 - Review. PMID 28290134
As such, these models can be used to study mechanisms of drug resistance and may provide a unique opportunity for identifying a truly novel antiseizure drug (ASD), but thus far clinical evidence for this hope is lacking. Although animal models of drug resistant seizures are now included in ASD discovery approaches such as the ETSP (epilepsy therapy screening program), it is important to note that no single model has been validated for use to identify potential compounds for as yet drug resistant seizures, but rather a battery of such models should be employed, thus enhancing the sensitivity to discover novel, highly effective ASDs. ...
As such, these models can be used to study mechanisms of drug resistance and may provide a unique opportunity for identifying a truly …
Future technologies for monitoring HIV drug resistance and cure.
Parikh UM, et al. Curr Opin HIV AIDS 2017 - Review. PMID 28059958 Free PMC article.
This review evaluates current and emerging technologies that are applicable for both surveillance of HIV drug resistance (HIVDR) and characterization of HIV reservoirs that persist despite antiretroviral therapy and are obstacles to curing HIV infection. ...
This review evaluates current and emerging technologies that are applicable for both surveillance of HIV drug resistance (HIVDR) and …
Biophysics in drug discovery: impact, challenges and opportunities.
Renaud JP, et al. Nat Rev Drug Discov 2016 - Review. PMID 27516170 Free article.
This Review provides a framework to understand this evolution by describing the key biophysical methods, the information they can provide and the ways in which they can be applied at different stages of the drug discovery process. We also discuss the challenges for current technologies and future opportunities to use biophysical methods to solve drug discovery problems....
This Review provides a framework to understand this evolution by describing the key biophysical methods, the information they can provide an …
Phenotypic screening in cancer drug discovery - past, present and future.
Moffat JG, et al. Nat Rev Drug Discov 2014 - Review. PMID 25033736
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. ...We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. ...
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approa …
An analysis of the attrition of drug candidates from four major pharmaceutical companies.
Waring MJ, et al. Nat Rev Drug Discov 2015 - Review. PMID 26091267
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. ...
The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce t …
The complex task of measuring intestinal permeability in basic and clinical science
Galipeau HJ and Verdu EF. Neurogastroenterol Motil 2016 - Review. PMID 27339216
Thus, reliable and sensitive methods to measure intestinal permeability in both the clinical and preclinical setting are needed. ...
Thus, reliable and sensitive methods to measure intestinal permeability in both the clinical and preclinical setting are needed. ...
Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
Schön T, et al. Clin Microbiol Infect 2017 - Review. PMID 27810467 Free article.
Drug-resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for Mycobacterium tuberculosis in cases of failure on standard therapy. ...Although multiresistant and extensively drug-resistant (MDR/XDR) tuberculosis is present worldwide, AST for M. tuberculosis (AST-MTB) is still mainly performed according to the resources available rather than the drug-resistance rates. ...
Drug-resistance testing, or antimicrobial susceptibility testing (AST), is mandatory for Mycobacterium tuberculosis in cases of failu
Target deconvolution from phenotype-based drug discovery by using chemical proteomics approaches.
Kubota K, et al. Biochim Biophys Acta Proteins Proteom 2019 - Review. PMID 30392561
Phenotype-based drug discovery is a key strategy for small molecule drug screening, and the molecular target identification of small molecules, termed "target deconvolution," is critical albeit challenging. ...
Phenotype-based drug discovery is a key strategy for small molecule drug screening, and the molecular target identification of …
Optimizing drug discovery by Investigative Toxicology: Current and future trends.
Beilmann M, et al. ALTEX 2019. PMID 30570669 Free article.
One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use of inappropriate animal models. Progress in Investigative Toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. ...
One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety …
Drug discovery through stem cell-based organoid models.
Ranga A, et al. Adv Drug Deliv Rev 2014 - Review. PMID 24582599
The development of new drugs is currently a long and costly process in large part due to the failure of promising drug candidates identified in initial in vitro screens to perform as intended in vivo. New approaches to drug screening are being developed which focus on providing more biomimetic platforms. This review surveys this new generation of drug screening technologies, and provides an overview of recent developments in organoid culture systems which could afford previously unmatched fidelity for testing bioactivity and toxicity. ...
The development of new drugs is currently a long and costly process in large part due to the failure of promising drug candidates ide …
593 results
Jump to page
Feedback